MK-571 (sodium)

MK-571 (L-660711) sodium is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1) . MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release[1][2][3].

Product Specifications

CAS Number

[115103-85-0]

Product Name Alternative

L-660711 (sodium)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Leukotriene Receptor; LPL Receptor; P-glycoprotein

Type

Reference compound

Related Pathways

GPCR/G Protein; Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/mk-571-sodium.html

Concentration

10mM

Purity

99.75

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

O=C(O[Na])CCSC(C1=CC=CC(/C=C/C2=NC3=CC(Cl)=CC=C3C=C2)=C1)SCCC(N(C)C)=O

Molecular Formula

C26H26ClN2NaO3S2

Molecular Weight

537.07

Precautions

H302, H315, H319, H335

References & Citations

Shipping Conditions

Room Temperature

Storage Conditions

4°C (Powder, sealed storage, away from moisture)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Isoform

LTD4/CysLT1; LTE4

Citation 01

Arch Toxicol. 2020 Nov;94 (11) :3799-3817.|Biomed Pharmacother. 2018 Oct:106:1563-1569.|Brain Res Bull. 2022 Oct 15:189:69-79.|Cancer Res Commun. 2024 Apr 9;4 (4) :1024-1040.|Cell. 2023 Dec 7;186 (25) :5500-5516.e21.|CNS Neurosci Ther. 2023 Jan;29 (1) :445-457.|Commun Biol. 2024 May 23;7 (1) :621.|Eberhard Karls Universität Tübingen. 2022 Feb.|Eur J Drug Metab Pharmacokinet. 2022 Mar;47 (2) :279-289.|Eur J Drug Metab Pharmacokinet. 2024 Sep;49 (5) :609-617.|Eur J Pharm Sci. 2023 May 1:184:106414.|Free Radic Biol Med. 2024 Jun 19:S0891-5849 (24) 00531-8.|Int J Nanomedicine. 2019 Nov 27;14:9217-9234.|J Appl Toxicol. 2024 Nov;44 (11) :1725-1741.|Pharmaceutics. 2024 May 29;16 (6) :731.|Pharmacol Res Perspect. 2022 Feb;10 (1) :e00928.|Regul Toxicol Pharmacol. 2019 Nov:108:104449.|Sci Adv. 2024 Dec 13;10 (50) :eadq4274.|Toxicol Lett. 2020 Jul 1;327:9-18.|Xenobiotica. 2020 Mar;50 (3) :354-362.|3 Biotech. 2025 Apr;15 (4) :72.|Adv Sci (Weinh) . 2025 Aug 4:e04680.|Biomed Pharmacother. 2020 Sep;129:110506.|Cell Death Discov. 2024 Aug 14;10 (1) :364.|Drug Metab Dispos. 2025 Sep 24.|J Drug Deliv Sci Technol. 2025 May.|J Pharm Biomed Anal. 2020 Sep 10;189:113441.|Nat Commun. 2023 Sep 19;14 (1) :5709.|Toxicology. 2025 Jun 3:154210.|Viruses. 2019 Apr 24;11 (4) :378.